MedStar Health, a major US health system headquartered in Columbia, Maryland, has entered a multi year strategic collaboration with Boston based PathAI to deploy the AISight Dx cloud native digital pathology platform and several AI applications across its laboratory network, supporting more than 40 pathologists and enhancing workflow efficiency in a multi site setup.
Glimpse:
Announced on April 7, 2026, the partnership includes implementation of PathAI’s FDA cleared AISight Dx platform for primary diagnosis, along with AI tools such as ArtifactDetect (for identifying slide preparation and scanning issues) and TumorDetect (research use only). The initiative builds on prior joint research, including validation of PathAI’s AIM-HER2 Breast algorithm, and will support future joint research, real world data development, clinical trials, and advanced AI diagnostics.
MedStar Health has teamed up with PathAI in a multi year agreement to modernize its pathology operations through widespread adoption of advanced digital tools. The collaboration focuses on deploying PathAI’s AISight Dx, a cloud native digital pathology image management system that integrates enterprise scale slide management, high quality image viewing, collaboration features, and seamless AI capabilities into one unified platform. This FDA-cleared solution is intended for primary diagnosis and will help standardize processes across MedStar Health’s multi site laboratory network while supporting clinical, research, and operational needs.
As part of the rollout, MedStar Health will incorporate additional AI-powered applications developed by PathAI. These include ArtifactDetect, which automatically flags issues related to slide preparation and scanning during daily workflows, and TumorDetect, currently available for research purposes only. Together, these tools aim to boost overall efficiency, reduce manual errors, and create more consistent laboratory practices for the health system’s team of over 40 pathologists. The deployment is expected to make pathology services more connected and scalable, especially as MedStar Health continues to grow its outreach business.
This strategic move builds upon MedStar Health’s earlier involvement in PathAI’s Early Access Program and previous collaborative research efforts, such as an independent validation study of the AIM-HER2 Breast algorithm. Looking ahead, the partnership will extend into joint research initiatives, creation of multimodal real world datasets, support for clinical trials, and development of next generation AI-enabled diagnostic solutions through PathAI’s Precision Pathology Network.
Leaders from both organizations see the collaboration as a significant step in leveraging digital pathology and artificial intelligence to improve diagnostic insights and scale high quality care across a large health system.
“At MedStar Health, we are focused on scaling high-quality care across a large and growing health system, including a rapidly expanding outreach business, and digital pathology is a critical enabler of that mission. By deploying AISight Dx and advanced AI applications, we are modernizing our pathology infrastructure in a way that makes us more connected, more efficient, and better positioned to bring innovative diagnostics into everyday practice.”
By
HB Team
Related News
